Thariat J, Marcié S, Marcy P-Y, Trimaud R, Angellier G, Mammar H, Bondiau P-Y, Gerard J-P
Université Nice-Sophia-Antipolis, Centre Antoine-Lacassagne, Département d'oncologie-radiothérapie, IBDC CNRS UMR, France.
Bull Cancer. 2010 Jul;97(7):807-18. doi: 10.1684/bdc.2010.1141.
Cyberknife (Accuray Inc. Sunnyvale, USA) stereotactic body radiation therapy (SBRT) involves the delivery of a small number of large doses of radiation to a target volume using continuously evolving advanced technology. It has emerged as a novel treatment modality for cancer and modified some concepts of cancer treatment. It is indicated in early-stage primary cancer, sometimes as an alternative to surgery. It is also indicated for patients with oligometastatic disease who have relatively long survival with the aim to optimize disease control with a good quality of life. Although there remain some uncertainties regarding the radiobiology of hypofractionation, local control and tolerance have been promising. Indications are increasing under strict quality assurance programs worldwide and prospective clinical evaluation.
射波刀（美国加利福尼亚州桑尼维尔市Accuray公司）立体定向体部放射治疗（SBRT）采用不断发展的先进技术，向靶区体积输送少量大剂量辐射。它已成为一种新型癌症治疗方式，并改变了一些癌症治疗观念。它适用于早期原发性癌症，有时可替代手术。它也适用于寡转移疾病患者，这些患者生存期相对较长，旨在以良好的生活质量优化疾病控制。尽管关于大分割放疗的放射生物学仍存在一些不确定性，但局部控制和耐受性前景良好。在全球严格的质量保证计划和前瞻性临床评估下，其适应证正在增加。
